Markets Update: September Turbulence

Episode Summary

Executive Summary: Tony Pascarello said September’s equity pullback looks more like a technical consolidation after a very strong summer rally than a fundamental break. He noted valuation remains rich versus history but more attractive relative to collapsing bond yields, while investors still focus on vaccine timing, fiscal policy, and the election.

Main Topics: September equity pullback after a strong summer rally (Priority: 5/5): U.S. stocks, especially Nasdaq and popular mega-cap names, sold off in early September after a powerful August advance, but Tony framed it as normal consolidation rather than a major reversal. Technical factors driving near-term weakness (Priority: 5/5): Tony emphasized heavy new issuance, cooling retail options activity, and reduced risk appetite as the main reasons for the retracement, more so than deteriorating fundamentals. Valuation remains expensive vs history but less so vs bonds (Priority: 4/5): He said traditional equity valuation metrics are still elevated, yet stock valuations look more reasonable when compared with very low and even negative real bond yields. Vaccine expectations remain central (Priority: 4/5): Investors are still watching vaccine news closely, and the base case remains approval by year-end and broad delivery in the first half of next year. Macro backdrop still supportive (Priority: 4/5): Despite September volatility, Tony argued monetary policy and global growth trends remain supportive, and stimulus effects should outlast the pandemic. Election and policy uncertainty as additional event risk (Priority: 3/5): Alongside the vaccine, the upcoming election and stalled fiscal negotiations add near-term uncertainty to markets.

Key Arguments: The September decline is mostly technical, not a sign that the broader bull market is over. Heavy equity issuance has forced portfolio managers to absorb a lot of new paper, creating near-term pressure. Retail demand for speculative risk cooled after historic July and August options volumes, reducing momentum. Traditional valuation metrics remain expensive, but equities compare favorably to extremely low bond yields. Market expectations for a vaccine are still high; approval by year-end and distribution in scale by Q2 next year remain the base case. Stimulus, monetary support, and global growth should continue to support risk assets despite temporary turbulence.

Data Points: Nasdaq decline from end-August: about 6% - Used as an example of September retracement in U.S. equities S&P 500 decline from end-August: about half of Nasdaq's drop - Illustrates that broader U.S. market weakness was milder than tech-heavy indices FANGMAN cohort decline since end-August: better part of 8% - Shows pressure in the most popular mega-cap stocks Non-dollar market performance: higher from end-August - EuroStoxx, Nikkei, and emerging markets were relatively stronger in September Nasdaq gain in August: over 11% - Highlights how strong the prior month had been before the September pullback Nasdaq performance since end-2018: essentially doubled - Provides longer-term context for why the September volatility may be less alarming New issue in equity and equity-linked offerings: up over 75% year-on-year - Supports the argument that supply pressure contributed to the pullback Traditional valuation metrics: 90th percentile or higher relative to history - Refers to P/E, price-to-book, and enterprise value-to-sales ratios Real U.S. government bond yields: negative across the entire curve - Explains why stocks can look cheaper relative to bonds than relative to history Vaccine approval expectation: at least one approval by year-end - Tony described this as the market's base case Vaccine distribution expectation: broad delivery by end of Q2 next year - Indicates expected timeline for scaling vaccine availability

Pivotal Quotes: "I tend to think the majority of this local pressure has been more technical in nature than anything else." — Tony Pascarello: Explaining why stocks weakened in September "on most any of the traditional valuation metrics for stocks, the market's still expensive." — Tony Pascarello: Discussing valuation compared with history "the base case seems consistent with what the base case from our own research team would be, which is we'll have at least one vaccine approval by the end of the year." — Tony Pascarello: Describing investor expectations for a COVID-19 vaccine

Implications: Listeners should view the September selloff as a pause rather than a regime change. Near-term volatility may persist, but supportive policy, vaccine progress, and low bond yields continue to underpin risk assets.